Home

MPM BIOVENTURES 2018, L.P.

CIK 1729505 · last filed 2026-09-03

MPM BIOVENTURES 2018, L.P. is a corporate insider who has filed 5 SEC Form 4 insider transactions across 2 companies since 2021. The most recent filing shows the insider sold $1.9M of TRDA on Sep 3, 2026. Across all open-market trades the lifetime net is −$17.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $29.5M across reported positions. The firm reports its address in Cambridge, MA. 28 SEC filings were submitted jointly with MPM BioVentures 2018 GP LLC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$29.47M

Companies

2

Total Filings

5

Lifetime Open-Market Net

-$17.93M

Filer Profile

Reported Address
450 KENDALL STREET
CAMBRIDGE, MA 02142
Phone
(617) 425-9200
State of Incorporation
DE
Related Filers
MPM BioVentures 2018 GP LLC — 28 joint filings, latest 2026-08-31
MPM BioVentures 2018 LLC — 28 joint filings, latest 2026-08-31
LUKE EVNIN — 6 joint filings, latest 2026-01-14
MPM ASSET MANAGEMENT INVESTORS BV2018 LLC — 6 joint filings, latest 2026-01-14
MPM BIOVENTURES 2018 (B), L.P. — 6 joint filings, latest 2026-01-14
Todd Foley — 4 joint filings, latest 2020-09-23
ANSBERT GADICKE — 2 joint filings, latest 2020-09-23
MPM Asset Management Investors BV2014 LLC — 2 joint filings, latest 2020-07-29
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TRDA 10%+ Owner 4,144,952 $7.11 $29.47M -$1.85M 1 2026-09-03
iTeos Therapeutics, Inc. (ITOS) Delisted 10%+ Owner 2,905,494 $10.15 $29.49M -$16.08M 4 2021-12-07

Recent Filings

5 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-03 TRDA Sell (S) −259,446 -$1.85M EDGAR
2021-12-07 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −149,493 -$5.04M EDGAR
2021-11-30 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −69,135 -$2.43M EDGAR
2021-09-13 iTeos Therapeutics, Inc. (ITOS) Delisted Sell (S) −172,920 -$4.90M EDGAR
2021-09-08 iTeos Therapeutics, Inc. (ITOS) Delisted Mixed −221,718 -$3.71M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.